CTOs on the Move

Sensorion

www.sensorion.com

 
Sensorion is a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation. Sensorion has entered into a broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.sensorion.com
  • 185 Alewife Brook Parkway Suite 210
    Cambridge, MA USA 02138
  • Phone: n/a

Executives

Name Title Contact Details
Bernd Schmidt
Chief Technical Officer Profile

Similar Companies

DermTech International

DermTech International is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cyagen

Cyagen Biosciences is an emerging and innovative biotechnology company that specializes in custom murine model generation, DNA vector construction and viral packaging services. We also offer a comprehensive catalog of stem cell lines, cell culture reagents and growth factors. Our rapidly expanding services portfolio features VectorBuilder – an online DNA vector construction platform designed to make tedious cloning projects obsolete. Let us provide the knowledge and resources to move your project forward, and get you back to discovery!

Capital Technology Information Services

Capital Technology Information Services is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Blue Sky Biotech Inc

Blue Sky Biotech Inc is a Worcester, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zevra Therapeutics

We are a rare disease therapeutics company leading with science to make life-changing therapeutics available to patients with significant unmet needs. We involve key thought leaders, physicians, patients, care partners, and advocacy groups in all of our clinical and regulatory development strategies. With a keen understanding that drug development often requires creative solutions, we have the insight and expertise to forge new pathways to success that others have missed. By following the data without bias, our transparent narratives and common-sense perspective have successfully overcome complex development challenges to make much-needed therapies available to patients. Nimble and dauntless, we push boundaries beyond what is thought to be possible and advance new therapies that have the potential to bring meaningful improvement to patients lives.